Background Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces
cardiovascular death and worsening heart failure in patients with chronic heart failure and …

Background The primary goals during acute heart failure (AHF) hospitalization are
decongestion and guideline-directed medical therapy (GDMT) optimization. Unlike diuretics …

Background Patients recently hospitalized for heart failure (HF) are at high risk for
rehospitalization and death. Objectives The purpose of this study was to investigate clinical …

Objective To determine the impact of sodium-dependent glucose type 2 cotransporter
inhibitors on the renal function in acute heart failure. Methods In a single-centre, controlled …

Importance Dapagliflozin was recently shown to reduce cardiovascular death or worsening
heart failure (HF) events in patients with HF with mildly reduced or preserved ejection …

Background: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse Outcomes in
Heart Failure), dapagliflozin, added to guideline-recommended therapies, reduced the risk …

Importance Dapagliflozin has been shown to reduce the risk of cardiovascular death or
worsening heart failure (HF) in patients with chronic HF and reduced ejection fraction …

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure and cardiovascular death among patients with chronic heart …

Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …

Aim We investigated the efficacy and safety of dapagliflozin, a sodium–glucose
cotransporter 2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) and heart failure …